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Abstract
Purpose—SEER registry data has been used to suggest underuse and disparities in receipt of
radiotherapy. Prior studies have cautioned that SEER may underascertain radiotherapy but lacked
adequate representation to assess whether underascertainment varies by geography or patient
sociodemographic characteristics. We sought to determine rates and correlates of
underascertainment of radiotherapy in recent SEER data.
Methods—We evaluated data from 2290 survey respondents with nonmetastatic breast cancer,
aged 20-79, diagnosed from 6/05-2/07 in Detroit and Los Angeles (LA) and reported to SEER
registries (73% response rate). Survey responses regarding treatment and sociodemographic
factors were merged to SEER data. We compared radiotherapy receipt as reported by patients
versus SEER records. We then assessed correlates of radiotherapy underascertainment in SEER.
Results—Of 1292 patients who reported receiving radiotherapy, 273 were coded as not receiving
radiotherapy in SEER (“underascertained”). Underascertainment was more common in LA than in
Detroit (32.0% vs 11.25%, p<0.001). On multivariate analysis, radiotherapy underascertainment
was significantly associated in each registry (LA, Detroit) with stage (p=0.008, p=0.026), income
(p<0.001, p=0.050), mastectomy receipt (p<0.001, p<0.001), chemotherapy receipt (p<0.001,
p=0.045), and diagnosis at a hospital that was not accredited by the American College of Surgeons
(p<0.001, p<0.001). In LA, additional significant variables included younger age (p<0.001), non-
private insurance (p<0.001), and delayed receipt of radiotherapy (p<0.001).
Conclusions—SEER registry data as currently collected may not be an appropriate source for
documentation of rates of radiotherapy receipt or investigation of geographic variation in the
radiation treatment of breast cancer.
Introduction
The National Cancer Institute's Surveillance Epidemiology and End Results (SEER)
Program began collecting cancer registry data in 1973. Currently, SEER collects data from
regional cancer registries that cover 26% of the U.S. population.1 These data include
information on cancer incidence, patient demographics, clinical and treatment factors, and
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survival, information of considerable relevance to those pursuing the agenda for
comparative effectiveness research in health care.
SEER data have been used to answer a variety of research questions.2 Several influential
studies have relied upon SEER data alone to determine the appropriateness of care delivered
to breast cancer patients, including rates of receipt of radiotherapy (RT) after breast
conserving surgery (BCS).34 These studies have suggested underuse of RT as well as
disparities in use by race, age, and geography.
The SEER program issues a standardized coding manual that indicates that all treatments
administered as part of the “first course” (which is defined in detail in the manual and is no
longer limited to a four month period of time) are to be considered for the radiation
treatment summary field.5 However, some studies have suggested that registry data may be
incomplete, particularly for treatments like RT that may be delivered in the outpatient
setting.67 These studies have led to some increased caution in use of SEER data alone, but
have not convinced researchers to abandon publishing studies of RT use based on analyses
of SEER data alone,8910 nor even always to acknowledge potential limitations. Furthermore,
existing studies assessing the adequacy of ascertainment of treatments in SEER registry data
have lacked adequate sample diversity by race, age, and geography to assess whether
ascertainment varies by these subgroups. In addition, rates of RT underascertainment may
have risen in recent years, with increasing use of chemotherapy prior to RT leading to the
delay of RT beyond a time period readily ascertained by registrars.
In light of these gaps in the literature, we conducted a study comparing SEER data on RT
receipt from two large regional registries to self-report by patients recently treated for breast
cancer in order to answer three questions. First, how well do these SEER registries ascertain
RT receipt in the current era; second, do different SEER sites differ in rates of RT
ascertainment; and third, if RT underascertainment exists, does it vary systematically by
clinical or sociodemographic factors?
Methods
Sampling and Data Collection
Details of the study design have been published elsewhere.111213 Women in the
metropolitan areas of Los Angeles (LA) and Detroit aged 21-79, diagnosed with Stage 0-314
primary ductal carcinoma in-situ or invasive breast cancer from June 2005 through February
2007 were eligible for sample selection. Latina (in LA) and African-American (in both LA
and Detroit) patients were over-sampled.
Eligible patients were selected using rapid case ascertainment as they were reported to the
LA Cancer Surveillance Program (LACSP) and the Metropolitan Detroit Cancer
Surveillance System (MDCSS) – SEER program registries. This method was used to obtain
a representative sample of cases sooner after diagnosis than can be provided by routine
ascertainment. We selected all African-Americans in both sites and all Hispanic patients in
LA followed by a random sample of non-African-American/non-Hispanic patients in both
regions to achieve the target sample size.13 Asian women in LA were excluded because
these women were being enrolled in other studies.
Physicians were notified of our intent to contact patients, followed by a patient mailing of
survey materials and $10 to eligible subjects. The questionnaire was translated into
Spanish15 and the Dillman method was employed to encourage response.16 The protocol
was approved by the Institutional Review Boards of the University of Michigan, University
of Southern California and Wayne State University.
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We accrued 3252 eligible patients, including approximately 70% of Latina and African-
American patients and 30% of non-Latina white patients diagnosed in LA and Detroit during
the study period. After initial selection, another 119 were excluded because 1) physician
refused permission to contact (n=20); 2) patient did not speak English or Spanish (n=17); 3)
patient was too ill or incompetent to participate (n=59); 4) patient denied having cancer
(n=23). Of the 3133 eligible patients included in the final accrued sample, 2290 (73.1%)
completed surveys and 2268 (72.4%) were later able to be matched to quality controlled
incident cases ascertained by the SEER registries. On average, patients were surveyed ten
months after diagnosis.
As shown in figure 1, 2179 patients responded to a question asking whether they had
received or planned to receive RT. We excluded the 237 patients who indicated they had yet
to begin RT at the time of the survey; we also excluded the 15 patients missing SEER data
on RT receipt, leaving 1927 patients for analysis.
Measures
We measured RT receipt by asking: “Did you or are you going to have radiation therapy to
treat your breast cancer?” We also asked about the timing of treatment (completed, started,
or planned), as well as whether initiation of RT had been delayed for any reason. As noted
above, those who reported that they planned to receive RT but had yet to start were excluded
from analysis, so that the self-reported measure of RT receipt in this study was considered
positive only for patients who reported already receiving radiation treatment.
We determined the final surgical procedure by asking about the initial surgical procedure
after biopsy and whether subsequent procedures were performed. We also assessed age,
race/ethnicity, comorbidities, insurance status at time of diagnosis, total household yearly
income at time of diagnosis, and educational attainment, through separate survey questions.
For age and race/ethnicity, we used SEER data for the few patients (<1%) missing data by
self report. We used SEER data for clinical information on tumor size and nodal status and
to identify hospital of diagnosis, which we then categorized based upon whether that
hospital was accredited by the American College of Surgeons (ACos).
To determine the RT receipt status in SEER registry data, we used the “radsum” variable,
the variable used to indicate any receipt of RT as part of initial therapy in the SEER
database. Those whom SEER coded as 0 (“none”) or 7 (“refused”) were coded as not
receiving RT; those whom SEER coded as codes 2-6 (codes for various modalities of RT)
were coded as receiving RT; the few who were coded as 9 (“unknown”) and 8
(“recommended; unknown if given”) were excluded from analysis as noted above.
We defined underascertainment as patient report of RT receipt among patients coded in
SEER as not having received RT.
Analysis
We compared self-reported data on RT receipt to RT as reported in SEER registry records.
We described the frequency of RT underascertainment in each SEER site. We then
calculated rates of underascertainment within each site after grouping patients by clinical
and sociodemographic characteristics, as well as by treatment and hospital characteristics.
We performed univariate analyses using chi-squared testing. We then regressed
underascertainment within each SEER site on stage, age, surgery type, race/ethnicity,
income, insurance, chemotherapy receipt, self-reported delay of RT initiation, and ACoS
accreditation status of the diagnosing hospital as independent variables, adjusting for
clustering by hospital. We evaluated all first-order interactions between significant
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variables, and none were significant except as reported. All results were weighted to account
for the sampling design and differential non-response. Results are presented as unweighted
values, with weighted percentages.
Results
Table 1 compares the RT receipt code in SEER to patient self-report. Of the 1292 patients
who reported receiving radiation, 273 were coded as not receiving RT in SEER
(“underascertained”). RT underascertainment was much more common in LA than in
Detroit (32.0% vs 11.25%, p<0.001).
In LA, RT underascertainment was more frequent in patients with higher stage, multiple
comorbidities, younger age, lower income, underinsurance, mastectomy receipt,
chemotherapy receipt, delayed initiation of RT, and diagnosis at an ACoS unaccredited
hospital (Table 2). In Detroit, patients with higher stage, mastectomy receipt, chemotherapy
receipt, and diagnosis at an unaccredited hospital were associated with higher rates of RT
underascertainment (Table 3).
On multivariate analysis, as shown in Table 4, RT underascertainment was significantly
associated in both registries (p values for LA, Detroit) with stage (p=0.008, p=0.026),
income (p<0.001, p=0.050), mastectomy receipt (p<0.001, p<0.001), chemotherapy receipt
(p<0.001, p=0.045), and diagnosis at a hospital that was not ACoS accredited (p<0.001,
p<0.001). In LA, additional significant variables included younger age (p<0.001), non-
private insurance (p<0.001), and delayed receipt of RT (p<0.001).
Discussion
The two SEER registries included in our study differed substantially in both rates and
correlates of RT underascertainment. RT underascertainment in LA was nearly three times
higher than in Detroit and was associated with age, insurance coverage, and delayed
initiation of RT in addition to variables that were significant in both locations (stage,
income, mastectomy receipt, chemotherapy receipt, and hospital accreditation status). These
results suggest that SEER registry data, collected by routine methods, may not be an
appropriate source for for documenting rates of RT receipt by breast cancer patients or for
investigating geographic variation in RT receipt.
SEER data alone have long been utilized to evaluate the appropriateness of breast cancer
treatment, including RT receipt. Nearly two decades ago, a seminal analysis of SEER data
from 1983-86 documented rates of RT receipt after BCS that varied significantly by
geography, race, and age.3 Another landmark study of SEER data from 1983-954 found a
decrease in the use of appropriate primary therapy for early-stage breast cancer over time
(with only 78% of women receiving appropriate primary therapy in 1995), driven by an
apparent increase in use of BCS that was not followed by RT or axillary surgery.
However, several studies have since raised questions about the completeness of registry
data, especially for treatments such as RT, which are often delivered in the outpatient
setting. Bickell and Chassin took data collected as part of a quality improvement project on
365 cases of Stage I-II breast cancer diagnosed between 1994 and 1996 at three New York
hospitals and compared them with data in the hospitals' tumor registries, finding that only
58% of RT was captured by the registries.6 Malin et al. compared California Cancer
Registry data with data abstracted from medical records of 304 patients in the PacifiCare of
California health plan who were diagnosed with breast cancer from 1993-95 in LA; they
found that only 72.2% of RT was captured by the registry.7 Given the sample size and the
fact that studied patients were older and less diverse than the LA population, the study's
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ability to detect sociodemographic differences was limited. Systematic differences in
ascertainment by disease stage were observed, however, and the authors noted that patients
with more advanced disease more often received treatment in the ambulatory setting that
was less likely to be reported to the registry.
Despite these studies, researchers have continued to use SEER data for evaluation of RT
receipt. For example, a study published this year used SEER data to study rates of RT
receipt among patients with locally advanced breast cancer, by race and surgery type.8 The
authors concluded that “rates of RT were low for all populations”; although they considered
a number of possible explanations for this finding, they did not mention the possibility of
RT underascertainment. They did state, “We considered RT use as a single surrogate marker
of quality cancer care, but there are certainly others. Rates of breast reconstruction and
adherence to hormonal or systemic therapy guidelines are all potential surrogate markers of
quality cancer care, but these data fields are either limited or unavailable in the SEER
database.” However, they did not consider the possibility that the RT field in the SEER
database might also have limitations. Ironically, in their introduction, the authors cited
Malin's study, but only in support of the statement, “Adherence to RT guidelines improves
overall and disease-specific survival and has been used as a surrogate marker of quality BCa
care.”
Other recent studies have acknowledged concerns about limitations of SEER registry data
but have dismissed these largely based upon comparisons to merged SEER-Medicare data.
For example, when Du and colleagues published an analysis of RT receipt based on SEER
data from 1992-2002,10 they referenced a study using merged SEER-Medicare data on
women aged 65-74 diagnosed with breast cancer in 1992, finding that among 2784 women
whom SEER recorded as not receiving RT, Medicare identified only 377 (13.5%) as
receiving RT.17 They also referenced a study18 of SEER-Medicare data from 1991-96 in
patients 65 and older that found 94% agreement between SEER and SEER-Medicare for RT
receipt in breast cancer patients, with only minimal variation between individual SEER
registries. Similarly, when Freedman and colleagues conducted a study using SEER data
from 1988-2004, they included an appendix assessing RT underascertainment using the
SEER-Medicare dataset from 1992-2002.9 They found 91% agreement between the two data
sources and concluded that “it is unlikely that our findings would be explained by problems
ascertaining radiation therapy by the SEER registries.” Reassured enough to consider SEER
data alone, they found a decrease in RT after BCS from 79% in 1988 to 66% in 2004, with
differences by race, SEER site, and age. These rates are markedly lower than those reported
by our patients in LA and Detroit in 2006.19
More recently, Dragun and colleagues published an interesting analysis that documented a
66% overall rate of radiation receipt, and significantly lower receipt in rural/Appalachian
populations, in the Kentucky Cancer Registry.20 These researchers discussed potential
limitations in registry data but noted that the KCR “has been awarded the highest level of
certification by the North American Association of Central Cancer Registries for an
objective evaluation of completeness, accuracy, and timeliness every year since 1997. The
KCR is also part of the … SEER program, which has the most accurate and complete
population-based cancer registry in the world.” Unfortunately, NAACCR accreditation does
not consider accuracy of coding of treatment receipt, including radiation receipt; it only
confirms that there is accuracy, completeness, and timeliness with respect to identification
of incident cases of cancer and demographic characteristics.21 Thus, while the study findings
may well reflect a true problem with undertreatment in settings where health care facilities
are more limited, one must exercise caution in drawing firm conclusions unless treatment
information in the Kentucky registry has been validated in ways not discussed in that
manuscript, as RT underascertainment may also be more likely in such settings.
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Of note, the current study shows that RT underascertainment appears to be more frequent
among younger patients not represented in SEER-Medicare comparisons and can occur even
in SEER registries holding NAACCR accreditation for high-quality incident case
ascertainment. Moreover, more breast cancer patients receive chemotherapy prior to RT
today than in the time periods of studies comparing SEER to SEER-Medicare data.
Although the first course of treatment is no longer defined by SEER as a four month period
from diagnosis, increased time between diagnosis and RT due to the administration of
chemotherapy increases the difficulty for registrars to ascertain radiation receipt. In light of
the findings of our current study, showing substantial RT underascertainment in one of the
largest SEER registries, we believe that future studies should not use the SEER dataset alone
to determine rates or correlates of RT receipt until the quality of the data in the other SEER
registries are investigated more closely.
Of note, SEER itself recognizes the limitations in registry data collected by routine methods
and so regularly also conducts ‘Patterns of Care’ studies focused on different cancer
sites.2223 These studies involve re-abstraction of treatment information from hospital records
and requests to physician offices to capture therapy administered in the outpatient setting.
Additional analysis using these methods would be valuable to assess rates of RT
underascertainment in other registry sites before further research relies upon SEER data
alone to assess RT receipt. Certainly, the findings of the current study are sobering.
The substantial differences in rates of ascertainment by the two registries we considered
likely reflect differences in the methods of surveillance. In the Detroit registry, surveillance
is active, and radiation facilities are surveyed as part of the process of incident case
identification, which also allows for updating of the radiation receipt variable. In the LA
registry, where surveillance is dependent upon reporting by registrars, it is not surprising
that rates of RT underascertainment are higher. Reporting of treatment received in the
outpatient setting is particularly difficult for registrars to capture. Moreover, in California,
the state law that established the registry system does not require capture of treatment given
outside the reporting facility. Thus, it is not surprising that RT underascertainment is
strongly associated with hospital accreditation status, as ACoS-accredited cancer programs
are required to capture all first course treatments regardless of location, in contrast to the
more basic requirements of state law that govern other institutions. The independent
association of numerous clinical and sociodemographic variables with ascertainment likely
reflects the way in which differences in these factors affect the timing of care and the type
and/or number of facilities within which these patients receive medical care.
This study has a number of strengths, including its large sample size and diverse population.
It also has several potential limitations. First, it relied upon self-report as the gold standard
to which SEER data were compared. Although we recognize that there is no true gold
standard, previous studies have supported the validity of self-report regarding RT and have
documented very high correlations between self-report and medical record review.242526
Criterion validity is supported by the fact that the overwhelming majority of patients who
reported receiving radiation went on to respond that they had received information regarding
management of RT side effects and reported receiving ≥5 weeks of treatment, as well as the
fact that self-reported receipt of radiation was highly correlated with clinical factors that
direct treatment recommendations.
Second, although this is the first study to our knowledge of RT underascertainment, other
than the SEER-Medicare studies, to include more than one geographic location, the study
was limited to two metropolitan SEER registries. It is therefore not possible to comment
definitively upon the rates of RT underascertainment in other registries, particularly more
Jagsi et al. Page 6
Cancer. Author manuscript; available in PMC 2013 January 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
rural registries. Nevertheless, these data are sufficient to conclude that RT
underascertainment is not uniform across SEER sites and can be quite substantial.
The call for comparative effectiveness research has led to heightened interest in the analysis
of population-based registry data. As increasing numbers of researchers begin to utilize
registry data, it is critical to evaluate the quality of those data. The SEER regional registry
network represents a golden opportunity to continue to build population-based translational
cancer research with real value to patients and their clinicians. Indeed, recent changes and
additions to the content of SEER data reflect the increasing complexity of clinical
information and treatment modalities for cancer and the interest of stakeholders in
enhancing the use of these data for purpose of assessing quality of care and outcomes.27
However, increased demand for breadth and depth of data against decreasing budgets for its
collection may be counterproductive. This study provides only one example of the ways in
which poor quality data misused may lead to spurious policy conclusions. One increasingly
common strategy to improve data quality is for registries to partner with investigators to use
supplemental research funding for special studies in cancer outcomes and effectiveness
research. Another strategy might be to allow and encourage regional SEER registries to
subspecialize in the collection of the more challenging and resource-intensive data elements
related the first course of therapy. This would create regional registries of excellence with
particular strengths in certain cancers or treatment modalities. The increasing complexity of
cancer care and increasing demand to evaluate it motivate creative solutions to ensure the
highest validity and quality of data collected by regional cancer registries.
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Figure 1. Source of Analyzed Sample
This flow diagram details the way in which the analytic sample was developed.
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Table 1
SEER Registry Data Compared with Patient Self Report of Radiotherapy (RT) Receipt
Patient Reports RT Receipt Patient Reports No RT Receipt
SEER Records RT Receipt 1019 (79%) 47 (7%)
SEER Records No RT Receipt 273 (21%) 588 (93%)
Total 1292 (100%) 635 (100%)
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Table 2
Characteristics of Patients Who Reported RT Receipt and Rates of Underascertainment
of RT by the Los Angeles SEER Registry
N Weighted % % Under-ascertained* P**
Stage <0.001
 0 (DCIS) 135 22 26
 I 290 48 26
 II 139 21 42
 III 70 9 47
Co-morbidity 0.001
 None 257 41 31
 1 198 33 28
 2+ 180 26 36
Age <0.001
 <50 165 22 43
 50-64 263 43 32
 65+ 207 34 23
Race 0.18
 Black 162 12 33
 White 184 65 29
 Hispanic 283 21 33
Income <0.001
 <$20,000 130 13 34
 $20,000-$69,999 234 37 38
 $70,000+ 129 30 27
 Unknown 142 21 24
Insurance <0.001
 None 58 5 51
 Medicaid 64 7 35
 Medicare 149 26 27
 Other 321 62 33
 Unknown 58 5 51
Surgery Type <0.001
 Breast conservation 548 87 28
 Mastectomy 87 13 51
Receipt of Chemotherapy <0.001
 Yes 260 35 45
 No 369 65 24
Delay in Initiating RT <0.001
 Yes 104 18 47
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N Weighted % % Under-ascertained* P**
 No 486 82 28
ACoS Acceditation of Diagnosing Hospital <0.001
 Yes 234 41 27
 No 387 59 33
*
% underascertained calculated within the weighted sample.
**
P values for differences in the proportion of RT receipt by the categories shown; separate category included for “unknown” when unknown
values exceeded 5% (income).
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Table 3
Characteristics of Patients Who Reported RT Receipt and Rates of Underascertainment
of RT by the Detroit SEER Registry
N Weighted % % Under-ascertained* P**
Stage 0.02
 0 (DCIS) 142 21 8
 I 251 40 8
 II 189 29 13
 III 68 11 14
Co-morbidity 0.14
 None 245 39 13
 1 202 31 8
 2+ 210 31 11
Age 0.06
 <50 162 25 14
 50-64 309 47 10
 65+ 186 28 9
Race 0.23
 Black 178 19 8
 White 446 76 12
 Other or unknown 33 6 6
Income 0.53
 <$20,000 87 12 11
 $20,000-$69,999 266 40 12
 $70,000+ 198 32 9
 Unknown 106 16 11
Insurance 0.50
 None 10 2 0
 Medicaid 36 5 10
 Medicare 182 28 11
 Other 420 66 11
 Unknown 10 2
Surgery Type <0.001
 Breast conservation 539 83 8
 Mastectomy 111 17 25
Receipt of Chemotherapy <0.001
 Yes 310 50 15
 No 308 50 7
Delay in Initiating RT 0.91
 Yes 113 18 11
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N Weighted % % Under-ascertained* P**
 No 507 82 11
ACoS Acceditation of Diagnosing Hospital <0.001
 Yes 424 68 9
 No 201 32 16
*
% underascertained calculated within the weighted sample.
**
P values for differences in the proportion of RT receipt by the categories shown; separate category included for “unknown” when unknown
values exceeded 5% (income).
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